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ABSTRACT
Objective: This report evaluates the acceptance, results, and predictors ofhuman immunodeficiency
virus (HIV) infection in inner city women referred to a colposcopy clinic for abnormal cervical
cytology.
Methods: HIV testing results of 1,908 inner city women referred for abnormal cervical cytology
were analyzed retrospectively with respect to acceptance, race, ethnicity, Pap smear results, sexu-
ally transmitted diseases (STDs), HIV exposures, and final histologic findings.
Results: HIV testing was accepted by 50.4% of patients. Women who agreed to screening were
significantly more likely to admit exposure to HIV or to be Hispanic, foreign-born, or have a history
of multiple STDs. Of those screened, 3.3% were found to be HIV seropositive. Although higher
grades of referral Pap smears were noted in the women found to be HIV seropositive, final histo-
logic findings were not different. The only predictors ofunknown HIV seropositivity were admitted
HIV exposure and external condyloma.
Conclusions: Fifty percent of inner city women of unknown HIV status referred for abnormal
cervical cytology will accept HIV serotesting and 3.3% are found to be positive. Most HIV-
seropositive women can be detected based on either a history of exposure to HIV or the presence
of external condyloma. Infect. Dis. Obstet. Gynecol. 4:281-286, 1996. (C) 1997 Wilcy-Liss, Inc.
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n association between human papillomavirus
(HPV)-related diseases of the cervix and hu-
man immunodeficiency virus (HIV) infection has
been recognized. HIV-infected persons have been
reported in several series to have increased rates of
HPV expression, increased rates of HPV-associated
intraepithelial lesions, and increased failure rates
following standard treatment for intraepithelial dis-
eases, e-4 Reports of more aggressive clinical
courses in patients with invasive cervical cancers
have led to inclusion of cervical cancer as an ac-
quired immunodeficiency syndrome (AIDS)-
defining illness.6 Additionally, HIV screening has
been recommended in patients with HPV-asso-
ciated intraepithelial and invasive neoplasms. 7
However, the extent to which HIV-infected indi-
viduals have contributed to an excess burden of
HPV-related diseases is unclear,s
In 1988, anonymous serum testing in New York
found 10% of women referred to an inner city col-
poscopy clinic to be HIV seropositive.
9 A prelimi-
nary report from our colposcopy clinic, located in a
teaching hospital serving primarily the East
Harlem community of New York, found 13 of 261
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women of unknown HIV serostatus referred for ab-
normal cervical cytology to be HIV seropositive.1
This report expands upon our preliminary report,
evaluates factors that predict acceptance of HIV
screening, and compares HPV-related disease in
HIV-seropositive and HIV-seronegative women.
SUBJECTS AND METHODS
From January 1, 1990, to December 1, 1994, all
women of unknown HIV serostatus referred to the
Mount Sinai Hospital for outpatient evaluation of
abnormal Pap smears were offered individual coun-
seling and screening for HIV. In compliance with
New York State legislation, all HIV counseling and
screening services were strictly confidential. Pre-
and post-test counseling were conducted by spe-
cifically trained personnel immediately following
colposcopy. If the patient agreed to HIV screening
after counseling, enzyme-linked immunosorbent
assay (ELISA) followed by Western blot confirma-
tion of positive results was performed. Separate
logbooks compiled computer-coded results that
were not linked to patient names to ensure confi-
dentiality.
All patients were queried regarding history of
sexually transmitted disease (STD), history of bi-
opsy-proven cervical intraepithclial neoplasia
(CIN), and specific exposure to HIV. Unless pre-
viously screened at the time of referral for abnor-
mal cervical cytology, patients were screened for
syphilis, Neisseria gonorrhoeae, and Chlamydia tracho-
matis by cultures or serology. At the time of initial
evaluation, the lower genital tract was carefully in-
spected for gross evidence of external condyloma.
A 3% acetic acid solution was used to cleanse the
cervix, after which the upper vagina and cervix
were visualized colposcopically with a 10x to 25x
lens. All colposcopic evaluations were performed
by residents in gynecology directly supervised by
specialists in gynecologic oncology. Biopsies and
endocervical curettage were performed in patients
in whom colposcopic evidence of CIN was seen.
Colposcopic evaluation and biopsies were per-
formed without regard to the results of HIV coun-
seling and screening. During subsequent visits, col-
poscopy and treatment were generally conducted
with knowledge of HIV test results.
Results were retrospectively compiled in a per-
sonal computer data base using both clinic records
and record of HIV serotesting. Comparative analy-
ses, including chi-square analysis and analysis of
variance (ANOVA), were performed with StatView
4.01 (Abacus Concepts, Berkeley, CA) with a sig-
nificance level of P 0.05. For estimation of the
predictive value for HIV seropositivity of selected
characteristics, odds ratios (ORs) with 95% confi-
dence intervals (CIs) were calculated. 13
RESULTS
Evaluation of All Patients
During the time of this study, 2,101 patients were
referred to the Mount Sinai Hospital Colposcopy
Clinic for colposcopic examination. Of these, 125
were known to be HIV scropositive at the time of
referral and were excluded. An additional 68 re-
cords had insufficient clinical material for evalua-
tion, leaving 1,908 patients for evaluation. Approxi-
mately 67% of the patients were referred from hos-
pital-based clinics, 25% from health department
clinics, and 8% from private physicians. The ma-
jority of women were referred for low grade squa-
mous intraepithelial lesions (LGSIL) (50%); lesser
numbers were referred for high grade squamous
intraepithclial lesions (HGSIL) (14%) or cancer
(0.7%) on Pap smear.
The population was predominantly young mi-
nority women, with a mean age of 29.3 years; only
8.6% were postmenopausal. Fifty-five percent
were Hispanic, 38% were African American, 7%
were white, and 0.3% were of other race. The me-
dian gravidity was two and median parity was one.
Reported current contraceptive practices of the
women included barrier methods (28%), oral con-
traceptives (21%), parentcral hormones (6%), sur-
gical sterilization (8%), and no contraception (38%).
Only 1.7% of the population recalled a history of
biopsy-confirmed CIN, but 22.5% reported a his-
tory of either gonorrhea, Chlamydia, or syphilis.
Five percent of the women in this clinic population
admitted current or past behavior which placed
them at risk for HIV acquisition, including injec-
tion drug use (IDU) in 1.4% and heterosexual con-
tact with men who were known or strongly sus-
pected to be HIV-infected in 2.9%. A small num-
ber of women (0.7%) reported other risks of HIV
exposure, including transfusion of blood products
between 1978 and 1985, living in an institutional
setting with other HIV-scropositivc individuals, or
occupational exposure.
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Analysis of Patients Based on Acceptance of
HIV Screening
Of the 1,908 patients for evaluation, 718 (37.6%)
refused both counseling and testing, 229 (12%)
agreed to counseling but refused antibody testing,
and 961 (50.4%) were counseled and agreed to
HIV-1 antibody testing. Women born outside the
United States wcrc significantly more likely to
agree to HIV screening than United States-born
women (P < 0.0001). Hispanic women tended to
agree to HIV screening more frequently than Afri-
can Americans (P 0.0004), and even United
States-born Hispanics were more likely to accept
HIV screening than United States-born African
Americans (P 0.034). Both younger and older pa-
tients were less likely to agree to HIV screening
than patients between the ages of 20 and 59 years.
Patients who accepted testing were significantly
more likely to admit exposure to HIV infection
than were patients who refused testing. The pa-
tients who refused HIV testing were more likely to
utilize barrier contraceptive methods, but overall
use of contraception did not differ based upon the
acceptance of HIV testing. No differences were
seen among the frequencies of prior CIN, STDs,
referral indications, smoking, or drug abuse. STD
testing for syphilis, gonorrhea, and Chlamydia did
not reveal any differences in overall frequency of
STDs (5.4% in those who accepted vs. 5.9% in
those who refused). Analysis of the patterns of test-
ing and acceptance of HIV testing by year (1990-
1994) did not reveal any significant change over the
5 years of this study.
Hispanic women who refused screening re-
ported significantly fewer exposures to HIV (P
0.031) and were less likely to have had a history of
STD (P 0.008) than the Hispanic women who
agreed to screening. Among non-Hispanic women,
no differences were found for the presence or ab-
sence of HIV exposure or history of STD based
upon the acceptance of HIV testing.
Results of HIV Screening in Those Who
Accepted Testing
Thirty-two patients, or 3.3% of the 961 who agreed
to screening, were identified as HIV seropositive.
Table demonstrates the comparisons among
those found to be HIV scropositive vs. those who
were HIV scronegative (one patient remained in-
TABLE I. Demographic analysis of patients who
accepted HIV screening
HIV HIV
positive negative
(N=32) (N=928)
Median age 31.4 years 29.5 years NS (ANOVA)
Premenopausal 100% 92.7% NS
Race
African American 25% 34.2% NS
Hispanic 71.4% 59.2% NS
White 3.6% 6.4% NS
Referral indications
Pap, atypia 26. I% 26.5% NS
LGSIL 44.8% 53.3% NS
HGSIL 31.0% 13.3% 0.007
Pap, cancer 0 0.7% NS
Pap, HGSIL
or cancer 31.0% 13.8% 0.01
External condyloma 3.4% 3.8% NS
History of CIN 0 1.5% NS
Any HIV exposure 43.8% 4.7% <0.0001
Any STD history 33.3% 20.6% NS
Not United
States-born 18.8% 21.4% NS
Gross external
condyloma 28. I% 7.0% 0.0004
Age at first
intercourse 16.5 years 16.2 years NS (ANOVA)
aNS not significant.
conclusive despite repeat testing 4 months later,
and was deleted from further analysis). The only
differences among these groups of patients were
admission of HIV exposure, presence of HGSIL on
referring Pap smear, and gross evidence of external
condyloma. Among both groups, the most common
high risk exposure was heterosexual exposure to
HIV-infected men, reported in 79% of those dem-
onstrated to be HIV seropositive.
During the 5 years of this study, there were mi-
nor fluctuations in the rates of unknown HIV se-
ropositivity found in this population, but in no year
did the yield ofHIV screening differ from the other
years by more than 1%. Patients under the age of
20 years and over the age of 50 years were signifi-
cantly less likely to be HIV seropositive (less than
0.01%) than those between 20 and 49 years.
Absolute CD4+ lymphocyte counts were avail-
able for 17 of the 32 newly diagnosed HIV-
seropositive patients. Only 2 of these 17 patients
had CD4+ counts less than 200/pl, and no other
AIDS-defining illness was noted among the newly
diagnosed HIV-seropositive patients within 4
months of diagnosis.
Women found to be HIV seropositive had a
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Fig. I. Comparison of final cervical diagnoses (combined histologic and colposcopic findings) by HIV seropositivity in all
patients who accepted HIV testing. Data are expressed in proportions of women in each group.
higher frequency of HGSIL or cancer on referring
cervical cytology smears than women demonstrated
to be HIV negative (31% vs. 13%; Table 1). The
final results of colposcopic evaluation and histo-
logic findings, however, demonstrate no significant
differences in the severity of cervical disease be-
tween the HIV-scropositive and HIV-seroncgative
women (Fig. 1). Even among women referred for
HGSIL or cancer on Pap smear, colposcopic and
histologic findings were similar for the HIV-
seropositivc and HIV-seroncgative women. None
of the HIV-seropositivc women were found to have
cervical cancer, while 12 HIV-scronegativc women
had cervical cancer (10 squamous cell carcinomas
and 2 cervical adenocarcinomas). This difference
was not statistically significant.
Analysis of Predictors of HIV Seropositivity
In an effort to delineate predictors of HIV seropos-
itivity in women with abnormal cervical cytology,
ORs with 95% CIs were calculated (Table 2). The
strongest risk factor for unknown HIV scropositiv-
ity was reported HIV exposure (OR 15.6, 95% CI
7.3-33.4). The presence of external condyloma of
the lower genital tract was also significantly associ-
ated with the finding of HIV seropositivity (OR
TABLE 2. ORs of predictors of unknown HIV
seropositivity in all women referred for abnormal
cervical cytology
OR CI
HIV exposure risk 15.6
History of STD 1.3
Either history of STD or HIV exposure 3.3
Not United States-born 0.9
African American race 0.6
Hispanic race 1.73
White race 0.54
Other cervical pathogens 1.56
LGSIL on referral cytology 0.72
HGSIL or cancer on referral cytology 2.6
External condyloma 5.8
7.3-33.4*
0.58-3.14
1.6-6.7*
0.3-2.
0.3-1.5
0.8-4.0
0.1-4.1
0.4-6.8
0.4-1.5
1.2-5.8*
2.6-13.1"
alncluding N. gonorrhea, Chlamydia, or syphilis (no prior history).
*Significant at P < 0.05.
5.8, 95% CI 2.6-13.1). HGSIL on referring cervical
cytology had a weak but significant association (OR
2.6, 95% CI 1.2-5.8) with HIV seropositivity when
analyzed with all patients. However, when patients
who reported exposure to possible HIV infection
were omitted in a subset analysis (i.e., analysis of
the 903 patients who denied HIV exposure, data
not shown), the association of HGSIL on referral
smear with HIV seropositivity was no longer sig-
nificant (95% CI now included one). In this subset
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analysis, the only association with HIV seropositiv-
ity in those women who denied exposure to HIV
infection was the presence of external condyloma.
Thirty-three percent of patients who denied expo-
sure to HIV but were found to be HIV seropositive
were noted to have external condyloma at the time
of initial colposcopic evaluation. In final analysis,
63% ofwomen in this sample who were found to be
HIV seropositive were noted to either admit expo-
sure to HIV or demonstrate gross evidence of ex-
ternal condyloma at the time of referral.
DISCUSSION
This study demonstrates the feasibility and results
of systematic HIV screening in women of unknown
HIV serostatus undergoing evaluation for abnormal
cervical cytology. In our population from an area of
high HIV endemicity, HIV screening was accepted
after counseling by approximately 50% of women.
This acceptance of HIV screening is similar to the
60% and 67% acceptance rates noted in the previ-
ous smaller studies by McCarthy et al. le and
Spitzer et al.,1 respectively. Approximately 3% of
our screened patients were identified as HIV-
infected by voluntary screening. Although this in-
cidence is clearly higher than that of reported se-
roprcvalcncc studies in female first-time blood do-
nors without reported risk factors,4 it is also less
than most reported prior seroprevalence estimates
in urban women referred for abnormal cervical cy-
tology in inner cities.
The scropositive yield of HIV screening in this
series was lower than in similar previous studies of
urban women. The reports from the boroughs of
Brooklyns and Queens in New York City may be
different duc to socioeconomic risk factors other
than abnormal cervical cytology. In the reports
from Queens, 8 of 132 inner city patients (6.1%)
were newly identified after referral to a colposcopy
clinic. In studies from Brooklyn, Fruchter and col-
leagues5 extrapolated that 13% of inner city col-
poscopy clinic patients were HIV scropositive.
However, the majority of the HIV-seropositive
women in their sample were known to be HIV-
infected prior to referral, such that the yield of HIV
screening in these 173 patients of unknown status
was only 6.4%. In our much larger sample of 961
inner city women of unknown serostatus who
agreed to HIV screening, only 3.3% of the patients
wcrc found to be HIV scropositivc.
In this study, women at higher apparent risk of
being HIV seropositive (because of admitted het-
erosexual HIV exposures) were more likely to par-
ticipate in HIV testing than those who refused test-
ing. HIV counseling was offered in both English
and Spanish, and Hispanic women were found to
be more likely to agree to screening. Hispanic
women who agreed to screening appeared to be at
higher risk of HIV infection based on higher rates
of self-reported HIV exposure. Unfortunately, Af-
rican American women with reported exposures to
HIV were equally likely to refuse or accept HIV
screening. This suggests HIV screening is poorly
accepted by African American women even in the
presence of risk factors for HIV infection.
Only one-half of the women who were demon-
strated to be HIV seropositive admitted exposure
to HIV. By observation of external condyloma as
well as exposure to HIV, however, we could have
correctly identified approximately two-thirds of our
otherwise-unsuspected HIV-scropositive women.
The association of external condyloma to HIV se-
roprcvalcnce in patients referred for abnormal cer-
vical cytology has been noted before. 13,5 In the
series from Brooklyn, the OR for condyloma with
HIV infection was 3.8 (confidence interval 1.0-
14.2), and was even more significant after control-
ling for age (OR 4.9).s In our series, not only was
external condyloma strongly associated with the
identification of HIV-scropositive patients, but ex-
ternal condyloma was the only independent pre-
dictor for the presence of HIV seropositivity in pa-
tients who deny or are not aware of exposure to
HIV-associatcd behavior.
Although previous studies have noted associa-
tions between HIV infection and high grade CIN/
cervical cancer, we saw little evidence of associa-
tion between biopsy-proven high grade CIN/
cancer and previously unsuspected HIV infection.
Most previous studies analyzed the cervical disease
in patients known to be HIV-infected, whereas our
HIV-infected patients were detected by systematic
screening. Therefore, those found to be HIV sero-
positive in this study may be earlier in the natural
history of their immunodeficiency than the HIV-
infected women described in previous reports. As
suggested by Smith et al.,6 it appears that severity
of cervical disease may be more dependent upon
the degree of immunodepression than on the pres-
ence or absence of HIV infection.
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It is possible that the more aggressive and ful-
minant courses of cervical cancer found in other
reports of HIV-infected women may have been
due to factors other than HIV infection alone. Cer-
vical carcinoma and its precursors share many risk
factors with heterosexually acquired HIV infection,
including substance abuse, non-white ethnicity,
lower socioeconomic status, concordant STD infec-
tions, multiple sexual partners, and high risk het-
erosexual behavior. These epidemiologic risk fac-
tors for cervical carcinoma are likely additive, such
that women with multiple risks may experience
more rapid progression. 17 Coupled with a lack of
any significant increase in the site-specific mortal-
ity from cervical cancer since the beginning of the
AIDS epidemic, 18,19 our results lead one to suspect
that HIV infection by itself may not necessarily
result in more rapid progression of HPV-related
disease in women,e
In conclusion, this report finds 3.3% of inner city
women with abnormal cervical smears to be HIV
seropositive at screening. Although high, this
prevalence is lower than previous reports from
similar urban areas where HIV infection is en-
demic. We found no evidence that cervical disease
is more aggressive in newly diagnosed asymptom-
atic HIV-infected women than in HIV-seroneg-
ative women. From these data, we estimate that
the risk of unknown HIV seropositivity in inner
city women with abnormal Pap smears is highest
between the ages of 20 and 49 years, in those who
admit to exposure to HIV, and in those who are
noted to have external condyloma on examination.
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